Press Room
Press Room 2023Press Releases 2023
Bonus BioGroup (TASE: BONS) is a clinical-stage Israeli biotechnology company, engaged in research and development of biomedical tissue-engineered and cell therapy products. Bonus Biogroup is pleased to announce entering an advanced stage in a joint trial in partnership with the Israel Institute for Biological Research (the "IIBR"). This study explores,…
Monday, 10 April 2023 15:00
Jackson Laboratories, USA, in collaboration with University College London Hospital, hosted a seminar in which Bonus Biogroup presented results demonstrating that:
The drug MesenCure reduced life-threatening cytokine release syndrome, which occurred as a result of immunotherapy for the treatment of cancer Bonus BioGroup (TASE: BONS) is a clinical-stage Israeli biotechnology company, engaged in research and development of biomedical tissue-engineered and cell therapy products. Bonus Biogroup is pleased to announce that Jackson…
Sunday, 26 February 2023 15:02
Bonus Biogroup Partners with St. Catherine's Hospital to Advance Clinical Trials of BonoFill and MesenCure in Europe
Collaboration with one of Europe's leading research centers in personalized medicine aims to accelerate clinical development. Bonus BioGroup (TASE: BONS) is a clinical-stage Israeli biotechnology company, engaged in research and development of biomedical tissue-engineered and cell therapy products. Bonus Biogroup is delighted to announce the signing of a strategic cooperation…
Thursday, 26 January 2023 14:56
Presentations to Highlight the Success of BonoFill at the 42nd Annual Conference of the Israeli Orthopedic Association
Orthopedic Surgeons to Showcase Successful Treatment of Bone Deficiencies with BonoFill, a Live Human Bone Graft by Bonus Biogroup Bonus BioGroup (TASE: BONS) is a clinical-stage Israeli biotechnology company, engaged in research and development of biomedical tissue-engineered and cell therapy products. Bonus Biogroup is pleased to announce that orthopedic surgeons…
Sunday, 15 January 2023 14:46
Success in obtaining certification of compliance with industrial manufacturing standards for Phase III clinical trial in severe COVID patients
The Israel Ministry of Health certified the facility and process for producing the investigational drug MesenCure to comply with Good Manufacturing Practices (GMP) according to the recommendations of the World Health Organization. Bonus BioGroup (TASE: BONS) is a clinical-stage Israeli biotechnology company, engaged in research and development of biomedical tissue-engineered…
BONUS BIOGROUP LTD.
info@bonus-bio.com
+972 (0)73 206 7104
Matam Advanced Technology
Park P.O.B 15143 Haifa 31905 Israel
 |
 |
 |
 |
© 2022 Bonus BioGroup Ltd. Created By Netron Israel Ltd